Quantitative assessment of the effects of sulfamethoxazole on Toxoplasma gondii loads in susceptible WT C57BL/6 mice as an immunocompetent host model

Parasitology International

Volumn 65, Issue 1, 2016, Pages 1-4

  Belal, Usama S ^a   Norose, Kazumi ^b   Mohamed, Rabie M ^a   Sekine, Shuichi ^b   Nukaga, Takumi ^b   Ito, Kousei ^b   Abdellatif, Manal Z ^a   Abdelgelil, Noha H ^a   Yano, Akihiko ^b  

^a Minia University   (Egypt)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Immunocompetent hosts; QC PCR; Sulfamethoxazole; Toxoplasma gondii

Indexed keywords

SULFAMETHOXAZOLE; COCCIDIOSTATIC AGENT; PROTOZOAL DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; HEART; HOST PARASITE INTERACTION; IMMUNOCOMPETENCE; INFECTION SENSITIVITY; LUNG; MOUSE; MOUSE MODEL; NONHUMAN; OUTCOME ASSESSMENT; PARASITE LOAD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENCE RISK; RECURRENT INFECTION; RISK REDUCTION; SKELETAL MUSCLE; SMALL INTESTINE; SURVIVAL RATE; TONGUE; TOXOPLASMA GONDII; TOXOPLASMOSIS; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; METABOLISM; PARASITOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

ANIMALS; BRAIN; COCCIDIOSTATS; DISEASE MODELS, ANIMAL; DNA, PROTOZOAN; HEART; IMMUNOCOMPETENCE; LUNG; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PARASITE LOAD; REAL-TIME POLYMERASE CHAIN REACTION; SULFAMETHOXAZOLE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

EID: 84942772073     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2015.09.004     Document Type: Article

References (24)

1. Dubey J.P. Advances in the life cycle of Toxoplasma gondii. Int. J. Parasitol. 1998, 28:1019-1024.
2. Norose K., Mun H.S., Aosai F., Chen M., Hata H., Tagawa Y., et al. Organ infectivity of Toxoplasma gondii in interferon-γ knockout mice. J. Parasitol. 2001, 87:447-452.
3. Leal F.E., Cavazzana C.L., de Andrade H.F., Galisteo A., de Mendonça J.S., Kallas E.G. Toxoplasma gondii pneumonia in immunocompetent subjects: case report and review. Clin. Infect. Dis. 2007, 44:e62-e66.
4. Habek M., Ozretić D., Zarković K., Djaković V., Mubrin Z. Unusual cause of dementia in an immunocompetent host: toxoplasmic encephalitis. Neurol. Sci. 2009, 30:45-49.
5. Nunura J., Vásquez T., Endo S., Salazar D., Rodriguez A., Pereyra S., et al. Disseminated toxoplasmosis in an immunocompetent patient from Peruvian Amazon. Rev. Inst. Med. Trop. Sao Paulo 2010, 52:107-110.
6. Wong W.K., Upton A., Thomas M.G. Neuropsychiatric symptoms are common in immunocompetent adult patients with Toxoplasma gondii acute lymphadenitis. Scand. J. Infect. Dis. 2013, 45:357-361.
7. Carme B., Demar M., Ajzenberg D., Dardé M.L. Severe acquired toxoplasmosis caused by wild cycle of Toxoplasma gondii, French Guiana. Emerg. Infect. Dis. 2009, 15:656-658.
8. Luo W., Aosai F., Ueda M., Yamashita K., Shimizu K., Sekiya S., et al. Kinetics in parasite abundance in susceptible and resistant mice infected with an avirulent strain of Toxoplasma gondii by using quantitative competitive PCR. J. Parasitol. 1997, 83:1070-1074.
9. Belal U.S., Norose K., Aosai F., Mun H.S., Ahmed A.K., Chen M., et al. Evaluation of the effects of sulfamethoxazole on Toxoplasma gondii loads and stage conversion in IFN-γ knockout mice using QC-PCR. Microbiol. Immunol. 2004, 48:185-193.
10. Shirakawa M., Sekine S., Tanaka A., Horie T., Ito K. Metabolic activation of hepatotoxic drugs (benzbromarone) induce mitochondrial membrane permeability transition. Toxicol. Appl. Pharmacol. Jul 3 2015, (pii: S0041-008X(15)30025-9 Epub ahead of print). 10.1016/j.taap.2015.06.018.
11. Suzuki Y., Kang H., Parmley S., Lim S., Park D. Induction of tumor necrosis factor-α and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-γ in genetically resistant BALB/c mice. Microbes Infect. 2000, 2:455-462.
12. Holland G.N., O'Connor G.R., Belfort R., Remington J.S. Toxoplasmosis. Ocular Infection and Immunity 1996, 1183-1223. Mosby, St. Louis, MO. J.S. Pepose, G.N. Holland, K.R. Wilhelmus (Eds.).
13. Rothova A., Meenken C., Buitenhuis H.J., Brinkman C.J., Baarsma G.S., Boen-Tan T.N., et al. Therapy for ocular toxoplasmosis. Am. J. Ophthalmol. 1993, 115:517-523.
14. Silveira C., Belfort R., Muccioli C., Holland G.N., Victora C.G., Horta B.L., et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 2002, 134:41-46.
15. Holland G.N. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am. J. Ophthalmol. 2004, 137:1-17.
16. Winterhalter S., Severing K., Stammen J., Maier A.K., Godehardt E., Joussen A.M. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:1187-1192.
17. Felix J.P., Lira R.P., Zacchia R.S., Toribio J.M., Nascimento M.A., Arieta C.E. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am. J. Ophthalmol. 2014, 157:762-766.
18. Di Cristina M., Marocco D., Galizi R., Proietti C., Spaccapelo R., Crisanti A. Temporal and spatial distribution of Toxoplasma gondii differentiation into bradyzoites and tissue cyst formation in vivo. Infect. Immun. 2008, 76:3491-3501.
19. Lyons R.E., McLeod R., Roberts C.W. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol. 2002, 18:198-201.
20. -/- mice. Parasitol. Res. 2007, 101:1603-1609.
21. Norose K., Aosai F., Mun H.S., Yano A. Effects of sulfamethoxazole on murine ocular toxoplasmosis in interferon-γ knockout mice. Invest. Ophthalmol. Vis. Sci. 2006, 47:265-271.
22. van der Ven A.J., Schoondermark-van de Ven E.M., Camps W., Melchers W.J., Koopmans P.P., van der Meer J.W., et al. Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. J. Antimicrob. Chemother. 1996, 38:75-80.
23. Dumas J.L., Pizzolato G., Pechère J.C. Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Int. J. Antimicrob. Agents 1999, 13:35-39.
24. Sabbagh N., Delaporte E., Marez D., Lo-Guidice J.M., Piette F., Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997, 7:131-135.